DNP - Der Neurologe und Psychiater

, Volume 14, Issue 6, pp 42–48

Neuropsychiatrische Störungen beachten

Idiopathisches Parkinson-Syndrom
Fortbildung
  • 16 Downloads

Zusammenfassung

Parkinson-Patienten leiden unter einer Vielzahl nicht motorischer Beschwerden, wie den neuropsychiatrischen Symptomen Depression, Angst oder Demenz, welche die Lebensqualität stark beeinträchtigen können. Ihre Diagnose wird allerdings durch die Überlappung mit motorischen Symptomen erschwert. Trotzdem ist die Therapie psychiatrischer Störungen immer ein notwendiger Bestandteil der Parkinson-Therapie, da sie die Lebensqualität der Patienten nachhaltig beeinflussen und viele der Symptome gut behandelbar sind.

Literatur

  1. 1.
    Parkinson, J., An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci, 2002. 14(2): p. 223–36; discussion 222.PubMedCrossRefGoogle Scholar
  2. 2.
    Poewe, W. and E. Luginger, Depression in Parkinson’s disease: impediments to recognition and treatment options. Neurology, 1999. 52(7 Suppl 3): p. S2–6.PubMedGoogle Scholar
  3. 3.
    Lemke M.R., C.-B.A.O., Depression bei Parkinon-Patienten. Dtsch. Ärztebl, 2002. 99(40): p. 2625–2631.Google Scholar
  4. 4.
    Dissanayaka, N.N., et al., Factors associated with depression in Parkinson’s disease. J Affect Disord, 2011. 132(1–2): p. 82–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Marsh, L., et al., Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord, 2006. 21(2): p. 148–58.PubMedCrossRefGoogle Scholar
  6. 6.
    Okun, M.S. and R.L. Watts, Depression associated with Parkinson’s disease: clinical features and treatment. Neurology, 2002. 58(4 Suppl 1): p. S63–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Reiff J, W.K., Deuschl G, Medikamentöse Therapie depressiver Störungen beim Morbus Parkinson. Akt. Neurol, 2005. 32: p. 77–85.CrossRefGoogle Scholar
  8. 8.
    Richard LH M.M., Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Hirn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W, A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology, 2012. 78: p. 1229–1236.PubMedCrossRefGoogle Scholar
  9. 9.
    Menza, M., et al., A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology, 2009. 72(10): p. 886–92.PubMedCrossRefGoogle Scholar
  10. 10.
    Wermuth, L., Sorensen PS, Timm S, Christensen B, Utzon NP, Boas J, Dupont E, Hansen E, Magnussen I, Mikkelsen B, Worm-Petersen J, Lauritzen L, Bayer L, Bech P., Depression in idiopathic Parkinson’s disease treated with citalopram. Nord J Psychiatry, 1998. 52(2): p. 163–169.CrossRefGoogle Scholar
  11. 11.
    Devos, D., et al., Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord, 2008. 23(6): p. 850–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Gallagher, D.A. and A. Schrag, Psychosis, apathy, depression and anxiety in Parkinson’s disease. Neurobiol Dis, 2012. 46(3): p. 581–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Aarsland, D., J. Zaccai, and C. Brayne, A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord, 2005. 20(10): p. 1255–63.PubMedCrossRefGoogle Scholar
  14. 14.
    Emre, M., Dementia associated with Parkinson’s disease. Lancet Neurol, 2003. 2(4): p. 229–37.PubMedCrossRefGoogle Scholar
  15. 15.
    Aarsland, D., et al., Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol, 2003. 60(3): p. 387–92.Google Scholar
  16. 16.
    Cummings, J.L., Intellectual impairment in Parkinson’s disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol, 1988. 1(1): p. 24–36.PubMedCrossRefGoogle Scholar
  17. 17.
    Dalrymple-Alford, J.C., et al., The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology, 2010. 75(19): p. 1717–25.PubMedCrossRefGoogle Scholar
  18. 18.
    Emre, M., et al., Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med, 2004. 351(24): p. 2509–18.PubMedCrossRefGoogle Scholar
  19. 19.
    Burn, D., et al., Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord, 2006. 21(11): p. 1899–907.PubMedCrossRefGoogle Scholar
  20. 20.
    Emre, M., et al., Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol, 2010. 9(10): p. 969–77.PubMedCrossRefGoogle Scholar
  21. 21.
    Fenelon, G. and G. Alves, Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci, 2010. 289(1–2): p. 12–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Baker, W.L., et al., Dopamine agonists in the treatment of early Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord, 2009. 15(4): p. 287–94.PubMedCrossRefGoogle Scholar
  23. 23.
    Stowe, R.L., et al., Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev, 2008(2): p. CD006564.Google Scholar
  24. 24.
    Eng, M.L. and T.E. Welty, Management of hallucinations and psychosis in Parkinson’s disease. Am J Geriatr Pharmacother, 2010. 8(4): p. 316–30.PubMedCrossRefGoogle Scholar
  25. 25.
    Condo, W.G., et al., Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord, 2005. 20(8): p. 958–63.CrossRefGoogle Scholar
  26. 26.
    Rabey, J.M., et al., Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord, 2007. 22(3): p. 313–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Weintraub, D., et al., Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol, 2010. 67(5): p. 589–95.PubMedCrossRefGoogle Scholar
  28. 28.
    Voon, V., et al., Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology, 2006. 66(11): p. 1750–2.PubMedCrossRefGoogle Scholar
  29. 29.
    Ondo, W.G. and D. Lai, Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord, 2008. 14(1): p. 28–32.CrossRefGoogle Scholar
  30. 30.
    Gallagher, D.A., et al., Pathological gambling in Parkinson’s disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord, 2007. 22(12): p. 1757–63.PubMedCrossRefGoogle Scholar
  31. 31.
    Voon, V., A.R. Mehta, and M. Hallett, Impulse control disorders in Parkinson’s disease: recent advances. Curr Opin Neurol, 2011. 24(4): p. 324–30.PubMedCrossRefGoogle Scholar
  32. 32.
    Avanzi, M., et al., Prevalence of pathological gambling in patients with Parkinson’s disease. Mov Disord, 2006. 21(12): p. 2068–72.PubMedCrossRefGoogle Scholar
  33. 33.
    Cilia, R., et al., Pathological gambling in patients with Parkinson’s disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov Disord, 2011. 26(2): p. 225–33.PubMedCrossRefGoogle Scholar
  34. 34.
    Weintraub, D., et al., Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol, 2010. 68(6): p. 963–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Thomas, A., et al., Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol, 2010. 68(3): p. 400–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Storch, A., et al., [Depression in Parkinson’s disease. Part 1: epidemiology, signs and symptoms, pathophysiology and diagnosis]. Fortschr Neurol Psychiatr, 2008. 76(12): p. 715–24.Google Scholar

Copyright information

© Urban & Vogel 2013

Authors and Affiliations

  1. 1.Klinik und Poliklinik für NeurologieTechnische Universität DresdenDresdenDeutschland

Personalised recommendations